{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-22-044329","form_type":"8-K","ticker":"ERNA","cik":"0000748592","company_name":"Ernexa Therapeutics Inc.","filed_at":"2022-12-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.491747+00:00","generated_at":"2026-06-21T09:53:26.373501+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Eterna closes ~$7.7M private placement with insider participation","bullets":["Closed private placement of 2,184,950 units at $3.53/unit on Dec 2, 2022, raising ~$7.7M.","Each unit consists of one share of common stock and two warrants exercisable at $3.28/share.","Warrants exercisable after 6 months, expire June 2, 2028; include 4.99%/9.99% beneficial ownership limit.","Chairman Cherington and director Singer participated on same terms as other investors.","Net proceeds to be used for general working capital."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-22-044329","json":"https://secwatch.observer/filing/0001140361-22-044329.json","markdown":"https://secwatch.observer/filing/0001140361-22-044329.md","text":"https://secwatch.observer/filing/0001140361-22-044329.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/748592/000114036122044329/0001140361-22-044329-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/748592/000114036122044329/brhc10045002_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T09:53:26.373501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4c1f4512ce95dd9c3c4e1d55dc101b69e4ae1867","claim":"Ernexa Therapeutics Inc. entered into Registration Rights Agreement with the Purchasers (effective 2022-12-02).","evidence_excerpt":"Pursuant to the Purchase Agreement, on the Closing Date, the Company and the Purchasers entered into a Registration Rights Agreement, pursuant to which the Company has agreed to prepare and file a registration statement on Form S-3 with the Securities and Exchange Commission no later than 30 days following the date on which the Company becomes eligible to use Form S-3 to register the resale of the shares of Common Stock included in the Units and the shares of Common Stock issuable upon exercise of the Warrants.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122044329/0001140361-22-044329-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Counterparty","value":"the Purchasers"},{"label":"Effective","value":"2022-12-02"}],"fact_type":"material_agreement"},{"claim_id":"c6efa9c128ec6194d7f11be90576eef659041346","claim":"Ernexa Therapeutics Inc. entered into Securities Purchase Agreement with certain investors (the \"Purchasers\") valued at approximately $7.7 million (effective 2022-11-23).","evidence_excerpt":"As previously reported, on November 23, 2022, Eterna Therapeutics Inc., a Delaware corporation (the “ Company ”), entered into a Securities Purchase Agreement (the “ Purchase Agreement ”) with certain investors (the “ Purchasers ”) providing for the private placement (the “ Private Placement ”) to the Purchasers of an aggregate of 2,184,950 units (collectively, the “ Units ”), each Unit consisting of (i) one share of the Company’s common stock, par value $0.005 per share (“ Common Stock ”) and (ii) two warrants, each exercisable to purchase one share of Common Stock (the “ Warrants ”), for an aggregate purchase price of approximately $7.7 million, consisting of $3.53 per Unit (inclusive of $0.125 per Warrant).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/748592/000114036122044329/0001140361-22-044329-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"certain investors (the \"Purchasers\")"},{"label":"Value","value":"approximately $7.7 million"},{"label":"Effective","value":"2022-11-23"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}